Literature DB >> 22180643

Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance.

Jona A Hattangadi1, Nathan Taback, Bridget A Neville, Jay R Harris, Rinaa S Punglia.   

Abstract

BACKGROUND: Accelerated partial breast irradiation using brachytherapy (APBIb) is an alternative to whole-breast irradiation (WBI) after breast-conserving surgery. We evaluated patterns of APBIb use with respect to 2009 American Society for Radiation Oncology consensus guidelines (ASTRO-G) in a population-based cohort.
METHODS: From Surveillance, Epidemiology, and End Results data, we identified 138 815 American women with breast cancer diagnosed between January 1, 2000, and December 31, 2007, who underwent WBI or APBIb after breast-conserving surgery and classified them as suitable, cautionary, or unsuitable for APBIb according to ASTRO-G criteria. Logistic regression was applied to study APBIb use overall and within each guideline category. All P values are from two-sided tests.
RESULTS: Overall, 2.6% of patients received APBIb, and 65.8% of them were classified as cautionary or unsuitable. APBIb was used by 5% of suitable, 3.4% of cautionary, and 1.6% of unsuitable patients by ASTRO-G criteria (P < .001). APBIb use increased from 0.4% in 2000 to 6.6% in 2007 and varied widely (0%-7%) between localities. Variables associated with APBIb use among suitable patients included other vs white race (odds ratio [OR] = 0.51, P < .001), region (OR = 2.60-8.62, P < .001), and more recent year (OR = 20.3, P < .001). Among cautionary patients, variables associated with APBIb use included black vs white race (OR = 0.76, P = .027), other vs white race (OR = 0.57, P < .001), Hispanic ethnicity (OR = 0.75, P = .036), region (OR = 3.10-10.2, P < .001), nonmetropolitan or rural location (OR = 0.53, P = .012), and more recent year (OR = 17.6, P < .001). Among unsuitable patients, black vs white race (OR = 0.77, P = .008), other vs white race (OR = 0.46, P < .001), region (OR = 3.33-21.6, P < .001), and more recent year (OR = 12.7, P < .001) were associated with APBIb use.
CONCLUSIONS: APBIb after breast-conserving surgery has been rapidly adopted in the United States. Use varied by race, ethnicity, and widely by region, especially among patients who may not be suitable for this radiation technique.

Entities:  

Mesh:

Year:  2011        PMID: 22180643     DOI: 10.1093/jnci/djr495

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

Review 1.  Race/Ethnicity and overuse of care: a systematic review.

Authors:  Nancy R Kressin; Peter W Groeneveld
Journal:  Milbank Q       Date:  2015-03       Impact factor: 4.911

2.  Utilization and Outcomes of Breast Brachytherapy in Younger Women.

Authors:  Grace L Smith; Jinhai Huo; Sharon H Giordano; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-14       Impact factor: 7.038

3.  Physician's peer exposure and the adoption of a new cancer treatment modality.

Authors:  Craig Evan Pollack; Pamela R Soulos; Cary P Gross
Journal:  Cancer       Date:  2015-04-22       Impact factor: 6.860

4.  Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer.

Authors:  Sounok Sen; Shi-Yi Wang; Pamela R Soulos; Kevin D Frick; Jessica B Long; Kenneth B Roberts; James B Yu; Suzanne B Evans; Anees B Chagpar; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2014-03-05       Impact factor: 13.506

5.  AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013.

Authors:  Anton Scharl; Christoph Thomssen; Nadia Harbeck; Volkmar Müller
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

6.  Accelerated partial breast irradiation through brachytherapy for ductal carcinoma in situ: factors influencing utilization and risks of second breast tumors.

Authors:  Ying Liu; Derek T Schloemann; Min Lian; Graham A Colditz
Journal:  Breast Cancer Res Treat       Date:  2015-04-19       Impact factor: 4.872

7.  For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery.

Authors:  Sounok Sen; Pamela R Soulos; Jeph Herrin; Kenneth B Roberts; James B Yu; Beth-Ann Lesnikoski; Joseph S Ross; Harlan M Krumholz; Cary P Gross
Journal:  Surgery       Date:  2013-12-15       Impact factor: 3.982

8.  Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer.

Authors:  Grace L Smith; Ying Xu; Thomas A Buchholz; Sharon H Giordano; Jing Jiang; Ya-Chen Tina Shih; Benjamin D Smith
Journal:  JAMA       Date:  2012-05-02       Impact factor: 56.272

9.  Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009.

Authors:  Carolyn J Presley; Pamela R Soulos; Jeph Herrin; Kenneth B Roberts; James B Yu; Brigid Killelea; Beth-Ann Lesnikoski; Jessica B Long; Cary P Gross
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

10.  Did the adoption of accelerated partial-breast irradiation reduce the noncompliance with adjuvant radiation in lumpectomy patients?

Authors:  Nengliang Yao; Abram Recht
Journal:  Am J Surg       Date:  2015-08-28       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.